Search jobs 11-Dec-2020 Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer
LOS ANGELES, Calif., December 11, 2020 / B3C newswire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncology Research, an
email article
Some women who are prescribed opioids and other drugs to ease pain after mastectomy and reconstructive surgery continue to use those medications, researchers reported.
In a large database analysis, new persistent use of opioids – defined as filling at least two prescriptions following surgery was observed among 13.1% of the women who underwent the breast cancer surgery, said Jacob Cogan, MD, of NewYork-Presbyterian Hospital/Columbia University Irving Medical School in New York City.
In addition, about 6.6% of women in the study who had been prescribed another class of addictive substances sedatives or hypnotics to help them deal with anxiety or insomnia after the surgery became persistent users of those medications as well, he said at at the virtual San Antonio Breast Cancer Symposium (SABCS).
email article
An oral taxane plus reduced-dose capecitabine increased the progression-free interval in metastatic breast cancer (MBC) by about 3 months, initial results from a randomized trial showed.
Patients treated with tesetaxel and capecitabine had a median progression-free survival of 9.8 months as compared with 6.9 months with capecitabine monotherapy. Two-thirds of patients in the tesetaxel arm had disease control at 24 weeks versus half of those in the placebo group, and the all-oral combination regimen led to significantly more objective responses.
The benefits were consistent across prespecified subgroups and occurred within the context of a manageable side-effect profile, Joyce O Shaughnessy, MD, of Baylor University Medical Center in Dallas, reported during the San Antonio Breast Cancer Symposium virtual meeting.
Combination therapy places no greater burden on early-stage breast cancer patients
Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women s Cancer Center investigators shows.
The report, coupled with earlier findings that combining checkpoint inhibitors with chemotherapy can increase response rates in patients with early-stage triple-negative breast cancer, offer assurance that the benefits of the combination can be achieved without diminishing patients quality of life, the study authors say.
The study, to be presented at today s virtual session of the San Antonio Breast Cancer Symposium, by Elizabeth Mittendorf, MD, PhD Director of the Breast Immuno-Oncology program at the Dana-Farber/Brigham and Women s Cancer Center, is the first to use patients own feedback to gaug
RxPONDER: Even More Women May Forgo Chemo for Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.